PCSS-MOUD Half and Half DEA Training

This training will be split between 2 dates, the first half on 8/4/2025 which will be held virtually and the second half which will be held in person on 8/11/2025 at the address included. To Register for the training please email: ppicare@icloud.com

Exchange Session 4 – Implement/Sustain

Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.

Exchange Session 3 – Implement/Sustain

Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.

Exchange Session 2 – Prepare

Review patient screening considerations and discuss how OUD screening can be integrated into current clinic workflows. Discuss the training and certifications required for specific team members to implement MOUD. Highlight the critical role of Champions, and how to strategically select Champions to support MOUD implementation.

Exchange Session 1 – Explore

Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical and financial considerations, and provide resources for both prescribers and non-prescribers.

The Importance of PAs in the Addiction Medicine Workforce

Join this PCSS-MOUD Clinical Roundtable which offers a chance to learn from and engage with our clinical experts! Lead Mentor Debra Newman, PA-C, MSPAS, MPH will The hour is comprised of a slide presentation and an open question session. Attendees will be given the opportunity to speak directly with the presenter to ask questions and discuss issues.